the world's headlines, one feed
Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
Hyperscalers' pain at the level of capex is a chipmaker's potential gain
Employers have grappled with soaring demand for GLP-1 drugs such as Ozempic and Wegovy, which can cost thousands of dollars per patient annually.
Parts of a SpaceX rocket reportedly crashed into the moon on Wednesday
Vancouver, B.C., Aug. 05, 2026 (GLOBE NEWSWIRE) — The Vancouver Fraser Port Authority will host its annual Port Day on Saturday, August 29, at Canada Place, inviting the community to learn about the…
What a difference a week makes. The S&P 500 has surged more than 6% over the past five days, its biggest gain since last year’s tariff tantrum.